antiretroviral therapy

Accelerated Epigenetic Aging in HIV: Insights from a Systematic Review

By MedXY 10/22/2025

Systematic review evidence supports accelerated epigenetic aging in people living with HIV compared to uninfected individuals, highlighting the need for further research considering antiretroviral therapy and confounding factors.

HIV/AIDS Infectious Diseases Specialties

Long-Term Health Risks in HIV Patients with Immune Non-Response Despite Antiretroviral Therapy

By MedXY 10/22/2025

Immune non-response despite ART in people with HIV significantly increases risk of both AIDS-defining and non-AIDS-defining comorbidities, underscoring the need for enhanced risk assessment beyond CD4+ T-cell counts.

Dermatology HIV/AIDS Specialties

Evolving Dermatologic Landscape in HIV: Prevalence, Incidence, and Risk Factors in the Modern ART Era from the DC Cohort

By MedXY 10/22/2025

Despite advances in antiretroviral therapy, dermatologic diseases remain prevalent in people with HIV, with incidence declining yet significant disparities persisting related to immune status, demographics, and structural factors.

HIV/AIDS Infectious Diseases Public Health Specialties

HIV Among Older Adults in Sub-Saharan Africa: Epidemiology, Risks, and Treatment Insights from the AWI-Gen Longitudinal Study

By MedXY 10/20/2025

This multicentre longitudinal cohort study reveals significant HIV prevalence and incidence among adults aged 40 and older in sub-Saharan Africa, highlighting age, gender, education, and rural residency as critical factors influencing HIV risk and treatment outcomes.

Cardiology HIV/AIDS news Specialties

Early HIV Treatment and Cardiovascular Health: Insights from the START Study

By MedXY 10/09/2025

Early ART initiation in HIV-positive adults with high CD4+ counts shows no overall cardiovascular benefit, but reduced CVD events in women suggest potential sex-specific effects needing further study.

HIV/AIDS news Specialties

Efficacy of Bictegravir-Based Regimen vs. Ritonavir-Boosted Protease Inhibitors in HIV Patients on Second-Line Therapy in Haiti: Insights from a Randomized Non-Inferiority Trial

By MedXY 09/21/2025

A randomized trial in Haiti demonstrates that switching to bictegravir, emtricitabine, and tenofovir alafenamide is non-inferior to ritonavir-boosted protease inhibitors in maintaining viral suppression among second-line HIV therapy patients.

Clinical Updates HIV/AIDS news Specialties

Comparative Effectiveness of Dolutegravir/Lamivudine Versus Bictegravir/Emtricitabine/Tenofovir Alafenamide for Maintenance Therapy in HIV: Insights from the PASO-DOBLE Trial

By MedXY 08/03/2025

The PASO-DOBLE trial demonstrated non-inferiority of dolutegravir/lamivudine versus bictegravir/FTC/TAF for maintenance in virologically suppressed HIV-1 adults, with similar efficacy and safety over 48 weeks.

Clinical Updates HIV/AIDS news Specialties

Advances in Second-Line Antiretroviral Therapy for Children with HIV in Africa: Insights from the CHAPAS-4 Trial

By MedXY 08/02/2025

TAF–emtricitabine and dolutegravir-based regimens outperform standard options as second-line ART for African children with HIV, offering improved viral suppression and safety.